p.20 抽出テキスト

104. Raposeiras-Roubin S, Rossello X, Oliva B, Fernandez-Friera L, Mendiguren JM, Andres V, et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol 2021;77: 3031–41. https://doi.org/10.1016/j.jacc.2021.04.059 105. Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 2015;2015:CD009580. https:// doi.org/10.1002/14651858.CD009580.pub2 106. Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563–74. https://doi.org/10.1056/NEJMoa1001282 107. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849–61. https:// doi.org/10.1016/S0140-6736(05)67667-2 108. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D’Emden MC, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780–8. https://doi.org/10.1016/S0140-6736(09)60698-X 109. Pradhan AD, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med 2022;387:1923–34. https://doi.org/10.1056/NEJMoa2210645 110. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J 2024;45:3538–700. https://doi.org/10.1093/eurheartj/ehae179 111. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792 112. Olshansky B, Chung MK, Budoff MJ, Philip S, Jiao L, Doyle RT Jr, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl 2020; 22(Suppl J):J34–48. https://doi.org/10.1093/eurheartj/suaa117 113. Ridker PM, Rifai N, MacFadyen J, Glynn RJ, Jiao L, Steg PG, et al. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1beta, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation 2022;146:372–9. https://doi.org/10. 1161/CIRCULATIONAHA.122.059410 114. U.S. Food & Drug Administration. Search Orphan Drug Designations and Approvals. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey= 480815 (22 October 2024, date last accessed). 115. Sherratt SCR, Libby P, Dawoud H, Bhatt DL, Mason RP. Eicosapentaenoic acid improves endothelial nitric oxide bioavailability via changes in protein expression during inflammation. J Am Heart Assoc 2024;13:e034076. https://doi.org/10.1161/JAHA.123. 034076 116. Sherratt SCR, Libby P, Bhatt DL, Mason RP. A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes. Prostaglandins Leukot Essent Fatty Acids 2022;182:102450. https://doi.org/10.1016/j.plefa.2022.102450 117. Alexander VJ, Karwatowska-Prokopczuk E, Prohaska TA, Li L, Geary RS, Gouni-Berthold I, et al. Volanesorsen to prevent acute pancreatitis in hypertriglyceridemia. N Engl J Med 2024;390:476–7. https://doi.org/10.1056/NEJMc2306575 118. Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med 2024;390:1770–80. https://doi.org/10.1056/NEJMoa2402309 119. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, et al. Olezarsen, acute pancreatitis, and Familial Chylomicronemia syndrome. N Engl J Med 2024;390:1781–92. https://doi.org/10.1056/NEJMoa2400201 120. Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, et al. Plozasiran for managing persistent chylomicronemia and pancreatitis risk. N Engl J Med 2025;392: 127–37. https://doi.org/10.1056/NEJMoa2409368 121. Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA interference agent targeting APOC3, for mixed hyperlipidemia. N Engl J Med 2024;391:899–912. https://doi.org/10.1056/NEJMoa2404143 122. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation 2018;138:1100–12. https://doi.org/10.1161/CIRCULATIONAHA.117.033369 123. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. Circulation 2023; 147:83–100. https://doi.org/10.1161/CIRCULATIONAHA.122.057443 124. Triant VA, Perez J, Regan S, Massaro JM, Meigs JB, Grinspoon SK, et al. Cardiovascular risk prediction functions underestimate risk in HIV infection. Circulation 2018;137: 2203–14. https://doi.org/10.1161/CIRCULATIONAHA.117.028975 125. Kentoffio K, Temu TM, Shakil SS, Zanni MV, Longenecker CT. Cardiovascular disease risk in women living with HIV. Curr Opin HIV AIDS 2022;17:270–8. https://doi.org/10. 1097/COH.0000000000000756 126. University of Liverpool. HIV Drug Interactions. https://www.hiv-druginteractions.org/ (27 July 2024, date last accessed). 127. Negredo E, Molto J, Puig J, Cinquegrana D, Bonjoch A, Perez-Alvarez N, et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006;20:2159–64. https:// doi.org/10.1097/01.aids.0000247573.95880.db 128. Chow D, Chen H, Glesby MJ, Busti A, Souza S, Andersen J, et al. Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. AIDS 2009;23:2133–41. https://doi.org/10.1097/ QAD.0b013e32833068e3 129. Saeedi R, Johns K, Frohlich J, Bennett MT, Bondy G. Lipid lowering efficacy and safety of ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis 2015;14:57. https://doi.org/10. 1186/s12944-015-0054-x 130. Boccara F, Kumar PN, Caramelli B, Calmy A, Lopez JAG, Bray S, et al. Evolocumab in HIV-infected patients with dyslipidemia: primary results of the randomized, doubleblind BEIJERINCK study. J Am Coll Cardiol 2020;75:2570–84. https://doi.org/10.1016/ j.jacc.2020.03.025 131. Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004;22: 1864–71. https://doi.org/10.1200/JCO.2004.06.033 132. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial. J Cardiovasc Pharmacol Ther 2019;24:233–41. https://doi.org/10.1177/1074248418821721 133. Hundley WG, D’Agostino R Jr, Crotts T, Craver K, Hackney MH, Jordan JH, et al. Statins and left ventricular ejection fraction following doxorubicin treatment. NEJM Evid 2022;1:10. https://doi.org/10.1056/EVIDoa2200097 134. Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, et al. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother 2023;9:515–25. https:// doi.org/10.1093/ehjcvp/pvad031 135. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244 136. D’Amario D, Laborante R, Bianchini E, Galli M, Ciliberti G, Mennuni M, et al. Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials. Int J Cardiol 2023;391:131219. https://doi.org/10.1016/j.ijcard.2023. 131219 137. Felix N, Nogueira PC, Silva IM, Costa TA, Campello CA, Stecca C, et al. Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: an updated meta-analysis of randomized controlled trials. Eur J Intern Med 2024;126:43–8. https://doi.org/10.1016/j.ejim.2024.04.007 138. Demonty I, Ras RT, van der Knaap HC, Duchateau GS, Meijer L, Zock PL, et al. Continuous dose-response relationship of the LDL-cholesterol-lowering effect of phytosterol intake. J Nutr 2009;139:271–84. https://doi.org/10.3945/jn.108.095125 139. The European Commission. Commission Regulation (EU) 2022/860 of 1 June 2022 Amending Annex III to Regulation (EC) No 1925/2006 of the European Parliament and of the Council as Regards Monacolins From Red Yeast Rice. https://eur-lex.europa.eu/ eli/reg/2022/860/oj (17 August 2024, date last accessed). Downloaded from academic.oup.com/eurheartj/article/46/42/4359/8234482 by guest on 07 October 2026